Châtillon, France, June 12, 2025
DBV Technologies to Participate in Upcoming
EAACI Congress 2025
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a
clinical-stage biopharmaceutical company, today announced upcoming
participation in the European Academy of Allergy and Clinical
Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United
Kingdom. DBV will present two posters and will also host a
symposium and exhibit booth in the EAACI exhibit hall.
Data to be presented during the scientific
sessions will describe the reduced rate of reactions from
accidental peanut consumption (APC) with the VIASKIN® peanut patch
versus placebo in Year 2 of the Company’s EPITOPE open-label
extension (OLE) trial, as well as data from the Company’s Phase 2
study (APTITUDE), which was conducted in collaboration with Nestlé
Health Science1, to evaluate the sensitivity, specificity and
safety of a VIASKIN® patch (DBV1605), for the diagnosis of non-IgE
mediated cow’s milk allergy in infants (>28 days old and ≤24
months).
“We are delighted to present the latest science
on our VIASKIN® patch platform at this year’s EAACI conference,
which is among the most prestigious and widely attended gatherings
of allergy experts and thought leaders from around the world,” said
Daniel Tassé, Chief Executive Officer, DBV Technologies. “Notably,
our symposium will offer new insights into epicutaneous
immunotherapy for peanut allergy, including a dynamic discussion
describing the clinical relationship between the allergist and the
patient. We are confident that our presentations at this year’s
EAACI conference will further advance our collective understanding
of epicutaneous immunotherapy as an exciting potential new
therapeutic option for food allergy.”
DBV’s symposium, “Peanut Allergy: Recent
Research Highlights”, will be co-chaired by Prof Gideon Lack,
Professor of Pediatric Allergy, London Allergy Care and Knowledge
and Prof Alexandra Santos, Professor of Pediatric Allergy, King’s
College London and Honorary Consultant in Pediatric Allergy at the
Evelina London Children’s Hospital. The symposium will include
lectures on the food-allergic patient/allergist clinical
relationship by Ozlem Ceylan, Chair of EAACI Patient Organization
Committee (for the patient’s perspective) and Prof Sophia Tsabouri,
University Hospital of Ioannina, Greece, and Chair of the EAACI
Pediatric Section (for the allergist’s perspective) , as well as a
presentation from Prof Katharina Blümchen, University Hospital
Frankfurt, Germany, who will describe new clinical data on
epicutaneous immunotherapy for peanut allergy.
“We look forward to sharing new clinical data
from year two of the EPITOPE open label extension highlighting
real-world protective effects of the VIASKIN® Peanut patch in
peanut-allergic toddlers,” said Dr. Pharis Mohideen, Chief Medical
Officer, DBV Technologies. “These data build upon results that were
shared at EAACI 2024 and demonstrate further reductions in
APC-related reactions with increased time on treatment. These
results from Year 2 of the EPITOPE open label extension suggest the
potential of VIASKIN® Peanut patch, if approved, to mitigate
reactions due to APCs, which we know are common, despite families
practicing strict avoidance. We also look forward to sharing the
results from the APTITUDE study, which, despite its early
termination due to enrollment difficulties in this patient
population and not as a result of any safety issues, are
nonetheless an encouraging step forward in demonstrating the broad
potential of the VIASKIN® patch in food allergy.”
Symposium
“Peanut Allergy: Recent Research
Highlights” will be co-chaired by Prof Gideon Lack and
Prof Alexandra Santos (UK)
- Date and location: Saturday, 14
June, 12:00 – 13:00 BST, Boisdale room
- Presentations:
- “Introduction," by
Prof Gideon Lack
- “The Allergist – Food
Allergic Patient Clinical Relationship” by Ozlem Ceylan
and Prof Sophia Tsabouri
- “Epicutaneous
Immunotherapy: New Data and Insights” by Prof Katharina
Blümchen
- “Conclusion,” by
Prof Alexandra Santos
Scientific Presentations
“Real-World Protective Effects of
Epicutaneous Immunotherapy in Peanut-allergic Toddlers”
will be presented by Dr. Jay A. Lieberman (USA)
- Session title: Moderated Poster
Walk, Allergen Immunotherapy 03
- Session date and time: Saturday, 14
June, 2025, 12:00 – 13:00 BST
- Session location: Poster zone
“Phase 2 Study to Evaluate the
Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic
Tool for Non–IgE-Mediated Cow’s Milk Allergy in Children
(APTITUDE)” will be presented by Prof Roberto Berni-Canani
(Italy)
- Session title: Practical Advances
in Food Allergy and Management
- Session date and time: Sunday, 15
June, 2025, 17:30 – 19:00 BST
- Session location: Dochart 1
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
VIASKIN® patch technology to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
VIASKIN® patch is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of VIASKIN Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital
Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding the therapeutic potential of
VIASKIN® Peanut patch and EPIT™, designs of DBV’s anticipated
clinical trials, DBV’s planned regulatory and clinical efforts
including timing and results of communications with regulatory
agencies, plans and expectations regarding initiation of the
confirmatory study, plans and expectations with respect to the
submission of BLAs to FDA, anticipated support for the BLA
submission, , and the ability of any of DBV’s product candidates,
if approved, to improve the lives of patients with food allergies.
These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, DBV’s product candidates have not been authorized for sale
in any country. Among the factors that could cause actual results
to differ materially from those described or projected herein
include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, and DBV’s ability to successfully execute on its budget
discipline measures. A further list and description of risks and
uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements in this
press release can be found in DBV’s regulatory filings with the
French Autorité des Marchés Financiers (“AMF”), DBV’s filings and
reports with the U.S. Securities and Exchange Commission (“SEC”),
including in DBV’s Annual Report on Form 10-K for the year ended
December 31, 2024, filed with the SEC on April 11, 2025, as amended
by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28,
2025, and as amended further by Amendment No. 2 on Form 10-K/A
filed with the SEC on May 14, 2025, and future filings and reports
made with the AMF and SEC by DBV. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Viaskin is a registered trademark and EPIT is a
trademark of DBV Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologiesangela.marcucci@dbv-technologies.com
1DBV and Societé des Produits Nestlé S.A
(formerly NESTEC S.A.) (“NESTEC”) agreed to terminate the
Development Collaboration and License Agreement, pursuant to which
this study was conducted, on October 30, 2023 .
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Juin 2025 à Juil 2025
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Juil 2024 à Juil 2025
